Reduced serum myostatin concentrations associated with genetic muscle disease progression. Burch, P. M., Pogoryelova, O., Palandra, J., Goldstein, R., Bennett, D., Fitz, L., Guglieri, M., Bettolo, C. M., Straub, V., Evangelista, T., Neubert, H., Lochmüller, H., & Morris, C. Journal of Neurology, 264(3):541–553, March, 2017. doi abstract bibtex Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC-MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.
@article{burch_reduced_2017,
title = {Reduced serum myostatin concentrations associated with genetic muscle disease progression},
volume = {264},
issn = {1432-1459},
doi = {10.1007/s00415-016-8379-6},
abstract = {Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC-MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.},
language = {eng},
number = {3},
journal = {Journal of Neurology},
author = {Burch, Peter M. and Pogoryelova, Oksana and Palandra, Joe and Goldstein, Richard and Bennett, Donald and Fitz, Lori and Guglieri, Michela and Bettolo, Chiara Marini and Straub, Volker and Evangelista, Teresinha and Neubert, Hendrik and Lochmüller, Hanns and Morris, Carl},
month = mar,
year = {2017},
pmid = {28074267},
keywords = {Adolescent, Adult, Aged, Aged, 80 and over, Animals, Blood Chemical Analysis, Child, Child, Preschool, Cohort Studies, Disease Progression, Female, Humans, Male, Mass Spectrometry, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Myostatin, Neuromuscular Diseases, Neuromuscular disease, Young Adult, biomarker},
pages = {541--553},
}
Downloads: 0
{"_id":"YcNGLnhL77QanY8bC","bibbaseid":"burch-pogoryelova-palandra-goldstein-bennett-fitz-guglieri-bettolo-etal-reducedserummyostatinconcentrationsassociatedwithgeneticmusclediseaseprogression-2017","author_short":["Burch, P. M.","Pogoryelova, O.","Palandra, J.","Goldstein, R.","Bennett, D.","Fitz, L.","Guglieri, M.","Bettolo, C. M.","Straub, V.","Evangelista, T.","Neubert, H.","Lochmüller, H.","Morris, C."],"bibdata":{"bibtype":"article","type":"article","title":"Reduced serum myostatin concentrations associated with genetic muscle disease progression","volume":"264","issn":"1432-1459","doi":"10.1007/s00415-016-8379-6","abstract":"Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC-MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.","language":"eng","number":"3","journal":"Journal of Neurology","author":[{"propositions":[],"lastnames":["Burch"],"firstnames":["Peter","M."],"suffixes":[]},{"propositions":[],"lastnames":["Pogoryelova"],"firstnames":["Oksana"],"suffixes":[]},{"propositions":[],"lastnames":["Palandra"],"firstnames":["Joe"],"suffixes":[]},{"propositions":[],"lastnames":["Goldstein"],"firstnames":["Richard"],"suffixes":[]},{"propositions":[],"lastnames":["Bennett"],"firstnames":["Donald"],"suffixes":[]},{"propositions":[],"lastnames":["Fitz"],"firstnames":["Lori"],"suffixes":[]},{"propositions":[],"lastnames":["Guglieri"],"firstnames":["Michela"],"suffixes":[]},{"propositions":[],"lastnames":["Bettolo"],"firstnames":["Chiara","Marini"],"suffixes":[]},{"propositions":[],"lastnames":["Straub"],"firstnames":["Volker"],"suffixes":[]},{"propositions":[],"lastnames":["Evangelista"],"firstnames":["Teresinha"],"suffixes":[]},{"propositions":[],"lastnames":["Neubert"],"firstnames":["Hendrik"],"suffixes":[]},{"propositions":[],"lastnames":["Lochmüller"],"firstnames":["Hanns"],"suffixes":[]},{"propositions":[],"lastnames":["Morris"],"firstnames":["Carl"],"suffixes":[]}],"month":"March","year":"2017","pmid":"28074267","keywords":"Adolescent, Adult, Aged, Aged, 80 and over, Animals, Blood Chemical Analysis, Child, Child, Preschool, Cohort Studies, Disease Progression, Female, Humans, Male, Mass Spectrometry, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Myostatin, Neuromuscular Diseases, Neuromuscular disease, Young Adult, biomarker","pages":"541–553","bibtex":"@article{burch_reduced_2017,\n\ttitle = {Reduced serum myostatin concentrations associated with genetic muscle disease progression},\n\tvolume = {264},\n\tissn = {1432-1459},\n\tdoi = {10.1007/s00415-016-8379-6},\n\tabstract = {Myostatin is a highly conserved protein secreted primarily from skeletal muscle that can potently suppress muscle growth. This ability to regulate skeletal muscle mass has sparked intense interest in the development of anti-myostatin therapies for a wide array of muscle disorders including sarcopenia, cachexia and genetic neuromuscular diseases. While a number of studies have examined the circulating myostatin concentrations in healthy and sarcopenic populations, very little data are available from inherited muscle disease patients. Here, we have measured the myostatin concentration in serum from seven genetic neuromuscular disorder patient populations using immunoaffinity LC-MS/MS. Average serum concentrations of myostatin in all seven muscle disease patient groups were significantly less than those measured in healthy controls. Furthermore, circulating myostatin concentrations correlated with clinical measures of disease progression for five of the muscle disease patient populations. These findings greatly expand the understanding of myostatin in neuromuscular disease and suggest its potential utility as a biomarker of disease progression.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Journal of Neurology},\n\tauthor = {Burch, Peter M. and Pogoryelova, Oksana and Palandra, Joe and Goldstein, Richard and Bennett, Donald and Fitz, Lori and Guglieri, Michela and Bettolo, Chiara Marini and Straub, Volker and Evangelista, Teresinha and Neubert, Hendrik and Lochmüller, Hanns and Morris, Carl},\n\tmonth = mar,\n\tyear = {2017},\n\tpmid = {28074267},\n\tkeywords = {Adolescent, Adult, Aged, Aged, 80 and over, Animals, Blood Chemical Analysis, Child, Child, Preschool, Cohort Studies, Disease Progression, Female, Humans, Male, Mass Spectrometry, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Myostatin, Neuromuscular Diseases, Neuromuscular disease, Young Adult, biomarker},\n\tpages = {541--553},\n}\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n","author_short":["Burch, P. M.","Pogoryelova, O.","Palandra, J.","Goldstein, R.","Bennett, D.","Fitz, L.","Guglieri, M.","Bettolo, C. M.","Straub, V.","Evangelista, T.","Neubert, H.","Lochmüller, H.","Morris, C."],"key":"burch_reduced_2017","id":"burch_reduced_2017","bibbaseid":"burch-pogoryelova-palandra-goldstein-bennett-fitz-guglieri-bettolo-etal-reducedserummyostatinconcentrationsassociatedwithgeneticmusclediseaseprogression-2017","role":"author","urls":{},"keyword":["Adolescent","Adult","Aged","Aged","80 and over","Animals","Blood Chemical Analysis","Child","Child","Preschool","Cohort Studies","Disease Progression","Female","Humans","Male","Mass Spectrometry","Mice","Inbred C57BL","Mice","Transgenic","Middle Aged","Myostatin","Neuromuscular Diseases","Neuromuscular disease","Young Adult","biomarker"],"metadata":{"authorlinks":{}},"downloads":0,"html":""},"bibtype":"article","biburl":"https://bibbase.org/zotero-group/kperon/94544","dataSources":["knnrEJWve9PHkHyWX"],"keywords":["adolescent","adult","aged","aged","80 and over","animals","blood chemical analysis","child","child","preschool","cohort studies","disease progression","female","humans","male","mass spectrometry","mice","inbred c57bl","mice","transgenic","middle aged","myostatin","neuromuscular diseases","neuromuscular disease","young adult","biomarker"],"search_terms":["reduced","serum","myostatin","concentrations","associated","genetic","muscle","disease","progression","burch","pogoryelova","palandra","goldstein","bennett","fitz","guglieri","bettolo","straub","evangelista","neubert","lochmüller","morris"],"title":"Reduced serum myostatin concentrations associated with genetic muscle disease progression","year":2017}